Here's Why Moderna Stock Got a Lift Today
Shares of Moderna (NASDAQ: MRNA) are on the move following the clinical-stage biopharmaceutical company's Research & Development Day presentation. Investors pleased with the path it's taking pushed its stock as much as 16% higher in Thursday morning trading, though those gains had moderated back to about 3% by around 2 p.m.
Moderna's messenger RNA (mRNA) platform has produced lots of new drug candidates ready for human studies, but we haven't seen any meaningful clinical data from them yet. At Thursday's R&D Day presentation, the company announced results from two phase 1 clinical trials that were as good as investors can hope for at this early stage.
Image source: Getty Images.
Source Fool.com
